Compare Amphastar Pharmaceuticals Inc (AMPH) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs New York Times Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while New York Times Co trades at $75 (market cap $12.13B). The key difference: New York Times Co is far larger — about 14.7× Amphastar Pharmaceuticals Inc's market cap, and New York Times Co pays a 1.23% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NYT | |
|---|---|---|
Market Cap | $826.08M | $12.13B |
Sector | Health | Media |
52-Week High | $30.81 | $85.86 |
52-Week Low | $16.87 | $51.43 |
Enterprise Value | $1.22B | $11.53B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
The New York Times (NYT) stock trades at $74.96, up 0.89% on the day, reflecting steady growth. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $0.61 surpassing the $0.47 expectation. Revenue reached $2.82B in 2025, with net income margin improving to 12.17%. Technical indicators show a bullish trend, while analyst consensus is a $78 price target. Recent news highlights legal actions involving OpenAI and government subpoenas, adding to operational scrutiny.
Outlook remains positive due to strong earnings performance and revenue growth, but risks include legal battles and regulatory pressures. The stock offers potential upside to the consensus target, supported by solid cash flow and profitability metrics. Investors should weigh these factors against ongoing litigation and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
